Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMIX NASDAQ:BRNS NASDAQ:MDXH NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$0.40$0.39$0.20▼$2.64$2.76M-1.821.90 million shs1.06 million shsBRNSBarinthus Biotherapeutics$0.69+0.9%$0.62$0.51▼$2.92$28.31M-0.4322,591 shs7,974 shsMDXHMDxHealth$0.80$2.17$0.68▼$5.33$39.60M1.61.06 million shs914,639 shsSYRESpyre Therapeutics$74.05$60.51$13.93▼$78.80$6.43B3.121.14 million shs574,914 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical0.00%+22.77%+8.31%+11.48%-77.33%BRNSBarinthus Biotherapeutics0.00%+1.97%+7.94%+19.46%+5.96%MDXHMDxHealth0.00%-10.41%-61.54%-77.84%-60.78%SYRESpyre Therapeutics0.00%-1.16%+6.29%+67.61%+393.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMIXAutonomix Medical$0.40$0.39$0.20▼$2.64$2.76M-1.821.90 million shs1.06 million shsBRNSBarinthus Biotherapeutics$0.69+0.9%$0.62$0.51▼$2.92$28.31M-0.4322,591 shs7,974 shsMDXHMDxHealth$0.80$2.17$0.68▼$5.33$39.60M1.61.06 million shs914,639 shsSYRESpyre Therapeutics$74.05$60.51$13.93▼$78.80$6.43B3.121.14 million shs574,914 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMIXAutonomix Medical0.00%+22.77%+8.31%+11.48%-77.33%BRNSBarinthus Biotherapeutics0.00%+1.97%+7.94%+19.46%+5.96%MDXHMDxHealth0.00%-10.41%-61.54%-77.84%-60.78%SYRESpyre Therapeutics0.00%-1.16%+6.29%+67.61%+393.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMIXAutonomix Medical 2.00Hold$2.00401.25% UpsideBRNSBarinthus Biotherapeutics 2.00Hold$4.00477.20% UpsideMDXHMDxHealth 2.50Moderate Buy$4.63478.13% UpsideSYRESpyre Therapeutics 3.00Buy$90.2521.88% UpsideCurrent Analyst Ratings BreakdownLatest AMIX, BRNS, SYRE, and MDXH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/14/2026MDXHMDxHealth TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00 ➝ $1.505/14/2026MDXHMDxHealth Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $5.005/14/2026MDXHMDxHealth William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/14/2026MDXHMDxHealth BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $4.005/12/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.005/8/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/6/2026SYRESpyre Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$92.00 ➝ $107.005/6/2026SYRESpyre Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$64.00 ➝ $97.005/4/2026AMIXAutonomix Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/22/2026BRNSBarinthus Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMIXAutonomix MedicalN/AN/AN/AN/A$3.29 per shareN/ABRNSBarinthus Biotherapeutics$14.97M1.89N/AN/A$1.63 per share0.43MDXHMDxHealth$110.97M0.36N/AN/A($0.41) per share-1.95SYRESpyre Therapeutics$890K7,225.28N/AN/A$5.93 per share12.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMIXAutonomix Medical-$11.41M-$3.55N/AN/AN/AN/A-228.82%-186.65%6/4/2026 (Estimated)BRNSBarinthus Biotherapeutics-$66.43M-$1.29N/AN/AN/AN/A-63.83%-48.77%8/6/2026 (Estimated)MDXHMDxHealth-$33.52M-$0.65N/AN/AN/A-29.90%-1,078.01%-22.51%8/13/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)Latest AMIX, BRNS, SYRE, and MDXH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2026N/AAMIXAutonomix Medical-$0.26N/AN/AN/AN/AN/A5/13/2026Q1 2026MDXHMDxHealth-$0.1447-$0.19-$0.0454-$0.17$30.89 million$23.90 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A4/30/2026Q1 2026BRNSBarinthus Biotherapeutics-$0.28-$0.14+$0.14-$0.14N/AN/A3/13/2026Q4 2025BRNSBarinthus Biotherapeutics-$0.40-$0.27+$0.13-$0.27N/AN/A2/27/2026Q4 2025MDXHMDxHealth-$0.13-$0.17-$0.04-$0.17$26.05 million$29.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMIXAutonomix MedicalN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AMDXHMDxHealthN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMIXAutonomix MedicalN/A6.186.18BRNSBarinthus BiotherapeuticsN/A6.056.05MDXHMDxHealthN/A1.631.46SYRESpyre TherapeuticsN/A8.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMIXAutonomix Medical10.78%BRNSBarinthus Biotherapeutics25.20%MDXHMDxHealthN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipAMIXAutonomix Medical6.20%BRNSBarinthus Biotherapeutics10.70%MDXHMDxHealth1.70%SYRESpyre Therapeutics15.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMIXAutonomix Medical16.91 million6.48 millionN/ABRNSBarinthus Biotherapeutics10740.85 million36.48 millionN/AMDXHMDxHealth30049.50 million48.66 millionNot OptionableSYRESpyre Therapeutics7386.84 million73.22 millionOptionableAMIX, BRNS, SYRE, and MDXH HeadlinesRecent News About These CompaniesPSP Research LLC Takes Position in Spyre Therapeutics, Inc. $SYREMay 20, 2026 | marketbeat.comLifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)May 18, 2026 | theglobeandmail.comUBS Group AG Has $22.30 Million Stake in Spyre Therapeutics, Inc. $SYREMay 12, 2026 | marketbeat.comVanguard Group Inc. Has $132.19 Million Stock Position in Spyre Therapeutics, Inc. $SYREMay 12, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Invests $547,000 in Spyre Therapeutics, Inc. $SYREMay 12, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year High - Time to Buy?May 11, 2026 | marketbeat.comF m Investments LLC Acquires 48,825 Shares of Spyre Therapeutics, Inc. $SYREMay 10, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Director Sells $5,952,000.00 in StockMay 9, 2026 | insidertrades.comMichael Thomas Henderson Sells 80,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockMay 8, 2026 | marketbeat.comSpyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $97.00 at CitigroupMay 6, 2026 | marketbeat.comSpyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for StockholdersMay 6, 2026 | tipranks.comSpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5, 2026 | globenewswire.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $892,125.00 in StockMay 2, 2026 | insidertrades.comSpyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million RaiseMay 1, 2026 | finance.yahoo.comInsider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 12,500 Shares of StockMay 1, 2026 | marketbeat.comInsider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of StockMay 1, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in StockMay 1, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3% - Here's What HappenedMay 1, 2026 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsMay 1, 2026 | globenewswire.comPictet Asset Management Holding SA Cuts Stake in Spyre Therapeutics, Inc. $SYREMay 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMIX, BRNS, SYRE, and MDXH Company DescriptionsAutonomix Medical NASDAQ:AMIX$0.40 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.39 -0.01 (-1.75%) As of 05/22/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.Barinthus Biotherapeutics NASDAQ:BRNS$0.69 +0.01 (+0.87%) Closing price 05/22/2026 03:57 PM EasternExtended Trading$0.70 +0.01 (+1.15%) As of 05/22/2026 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.MDxHealth NASDAQ:MDXH$0.80 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.82 +0.02 (+2.50%) As of 05/22/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Spyre Therapeutics NASDAQ:SYRE$74.05 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$73.40 -0.65 (-0.88%) As of 05/22/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
